AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02091739
Drug: IncobotulinumtoxinA (75 Units)
RxNorm normalized name: incobotulinumtoxinA 100 UNT
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Trial: NCT02086552
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02086552
Drug: Sonidegib
RxNorm normalized name: Sonidegib
DrugBank: Sonidegib (DB09143)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01705808
Drug: Protein C concentrate
RxNorm normalized name: PROTEIN C CONCENTRATE
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01357109
Drug: Bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 62.5 mg bid for two weeks and 125 mg bid for two weeks
Trial: NCT03088358
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00345163
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT00345163
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT03579914
Drug: Metoprolol Injectable Product
RxNorm normalized name: metoprolol Injectable Product
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive intravenous Metoprolol injection
Trial: NCT02989272
Drug: Sulfate, Magnesium
RxNorm normalized name: Sodium Picosulfate, Magnesium Oxide, and Citric Acid for Oral Solution
DrugBank: Zinc sulfate, unspecified form (DB14548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: magnesium group (30 patients) who will receive pretreatment by intravenous infusion of magnesium sulfate 60 mg / kg
Trial: NCT00263484
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
Trial: NCT00263484
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
Trial: NCT01339871
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose 400 mg orally daily of 28 day cycle.
Trial: NCT01339871
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose 100 mg orally daily of 28 day cycle.
Trial: NCT01421498
Drug: Lifitegrast
RxNorm normalized name: Lifitegrast
DrugBank: Lifitegrast (DB11611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: 12 weeks
Trial: NCT01205321
Drug: Bombesin (68Ga) labeled (BAY86-7548)
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Bombesin (DB11724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer patients, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, PET/CT
Trial: NCT01205321
Drug: Bombesin (68Ga) labeled (BAY86-7548)
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Bombesin (DB11724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY86-7548 in blood
Trial: NCT01797341
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01108510
Drug: COBI
RxNorm normalized name: Ricobid H
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cobicistat (COBI) 150 mg tablet administered orally once daily
Trial: NCT01016223
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate 80 mcg two puffs twice daily for 8 weeks
Trial: NCT00174356
Drug: CI 1033
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00174356
Drug: PACLITAXEL
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00174356
Drug: CARBOPLATIN
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00957996
Drug: Peramivir
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg twice daily
Trial: NCT00957996
Drug: Peramivir
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg once daily
Trial: NCT03948464
Drug: Slow release oral morphine (SROM)
RxNorm normalized name: morphine Extended Release Oral Tablet
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slow release oral morphine is an opioid agonist. Slow release oral morphine will be administered via daily witnessed ingestion at designated community pharmacies.
Trial: NCT03948464
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methadone is an opioid agonist. Methadone will be administered via daily witnessed ingestion at designated community pharmacies.
Trial: NCT01108510
Drug: ATV
RxNorm normalized name: PrenatVite Tablet
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atazanavir (ATV) 300 mg capsule administered orally once daily
Trial: NCT02156336
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration, BID; for a maximum of 51 days.
Trial: NCT03246659
Drug: 111In-CP04
RxNorm normalized name: 111In-Pentetreotide
DrugBank: Indium In-111 pentetreotide (DB11835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiopharmaceutical preparation
Trial: NCT01356992
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs will be provided by the sponsor to the study's patients on the reference presentation: 40 mg/0.4mL, 60 mg/0.6 mL and 80 mg/0.8 mL (solution for injection of enoxaparin sodium, 1 mg/ kg Sanofi-Aventis) or Eurofarma enoxaparin sodium (1 mg/ kg). The patients will use the drug corresponding to the arm of the study to which they were allocated. The drug administration must be performed through subcutaneous via on the dose of 1 mg/kg every 12 hours for at least 2 days and kept until the patient is discharged.
Trial: NCT02955706
Drug: Acetyl-L-Carnitine
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TID
Trial: NCT02077400
Drug: Cephazolin
RxNorm normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cephazolin
Trial: NCT03549559
Drug: 11C-Martinostat
RxNorm normalized name: 11C-choline
DrugBank: Martinostat (DB14979)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaging probe for evaluating the activity of histone deacetylase in the heart
Trial: NCT02955706
Drug: Placebo of Acetyl-L-Carnitine
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TID
Trial: NCT00781534
Drug: Ginseng
RxNorm normalized name: Ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each of the 3 arms will be compared to determine if there is any clinical difference in blood sugars between the 3 groups
Trial: NCT00781534
Drug: Ginseng
RxNorm normalized name: Ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00781534
Drug: ginsenoside RE
RxNorm normalized name: Ginsenoside Re
DrugBank: Ginsenoside B2 (DB14815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active metabolite of ginseng
Trial: NCT02327273
Drug: BMS-963272
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00344006
Drug: chlorproguanil-dapsone-artesunate
RxNorm normalized name: Artesunate
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00419653
Drug: Amisulpride
RxNorm normalized name: Amisulpride
DrugBank: Amisulpride (DB06288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00419653
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00113269
Drug: basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV
Trial: NCT00419653
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00113269
Drug: rabbit anti-thymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00113269
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00113269
Drug: alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV)
Trial: NCT00113269
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT04290611
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide for the treatment of prostate cancer or other solid tumors
Trial: NCT02851849
Drug: LGD-6972-5 mg
RxNorm normalized name: LGD-6972
DrugBank: LGD-6972 (DB14779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg LGD-6972 QD
Trial: NCT02851849
Drug: LGD-6972-10 mg
RxNorm normalized name: LGD-6972
DrugBank: LGD-6972 (DB14779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg LGD-6972 QD
Trial: NCT02851849
Drug: LGD-6972-15 mg
RxNorm normalized name: LGD-6972
DrugBank: LGD-6972 (DB14779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg LGD-6972 QD
Trial: NCT00004478
Drug: droxidopa
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01171183
Drug: controlled release carvedilol
RxNorm normalized name: carvedilol Extended Release Oral Capsule
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper
Trial: NCT00200512
Drug: apomorphine HCl injection
RxNorm normalized name: apomorphine hydrochloride Injectable Product
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00273559
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: group 2 will remain on 5 mg of prednisone for at least 90 days post transplant.
Trial: NCT00350701
Drug: androgel
RxNorm normalized name: AndroGel
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: androgel 5g
Trial: NCT04260464
Drug: PF-06700841
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 30 mg PF-06700841 will be administered on Day 1
Trial: NCT02766348
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine 1000mg/m2 IV on day 1 an day 8, repeat every 3 weeks
Trial: NCT00835510
Drug: Butenafine cream 1% manufactured by Taro
DrugBank: Butenafine (DB01091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment applied to affected area twice daily for 7 days
Trial: NCT00835510
Drug: Butenafine Vehicle manufactured by Taro
DrugBank: Butenafine (DB01091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment applied to affected area twice daily for 7 days
Trial: NCT00154427
Drug: activated recombinant human factor VII
RxNorm normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00350701
Drug: androgel 10g
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: androgel 10g
Trial: NCT02766348
Drug: cisplatinum
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
Trial: NCT01462630
Drug: pazopanib hydrochloride
RxNorm normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT03145467
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
Trial: NCT03145467
Drug: Zolmitriptan
RxNorm normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients
Trial: NCT00779584
Drug: MK-8776
RxNorm normalized name: MK-8776
DrugBank: MK-8776 (DB11899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT00779584
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT03102658
Drug: Micafungin
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of study drug
Trial: NCT01735318
Drug: Lisinopril Tablets 40 mg
RxNorm normalized name: lisinopril Oral Tablet
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg tablet once a day
Trial: NCT01735318
Drug: Lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg tablet once a day
Trial: NCT00130507
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00130507
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01765296
Drug: CG100649
DrugBank: G100 (DB17244)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg capsule
Trial: NCT01302405
Drug: PRI-724
RxNorm normalized name: PRI-724
DrugBank: PRI-724 (DB15034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation
Trial: NCT03582384
Drug: Tocofersolan
RxNorm normalized name: tocofersolan
DrugBank: Tocofersolan (DB11635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After baseline labs are obtained, therapy with tocofersolan will be initiated at an initial dose of 17 mg/kg of d-alpha-tocopherol in the form of tocofersolan (0.34 ml/kg/day) and titrated based on blood levels.
Trial: NCT04358016
Drug: Terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluate the effect of Terlipression on the occurance of acute kidney injury in patients with upper-gastroentestinal bleeding
Trial: NCT04358016
Drug: Somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin
Trial: NCT00970489
Drug: Omega -3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.
Trial: NCT01395849
Drug: Salmeterol and Fluticasone
RxNorm normalized name: salmeterol and fluticasone
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01502306
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clients will be screened for contraindications to nicotine patch use, and a doctor's approval will be necessary before patches are sent if a contraindication exists.
Trial: NCT00695136
Drug: Donepezil hydrochloride
RxNorm normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03469492
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin regimens will be adjusted on a weekly basis as needed to achieve a target blood glucose level.
Trial: NCT01726049
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks
Trial: NCT03090971
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following microporation, control neurofibromas will receive treatment with topical saline
Trial: NCT00370370
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injection of intravitreal bevacizumab
Trial: NCT00370370
Drug: bevacizumab + triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injection of bevacizumab + triamcinolone acetonide
Trial: NCT02507687
Drug: Bimatoprost SR
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost SR is a biodegradable, sustained-release, preservative-free bimatoprost implant, preloaded in an applicator for administration. The Bimatoprost SR implant is injected into the anterior chamber via the corneal limbus using the prefilled applicator.
Trial: NCT02507687
Drug: Sham Bimatoprost SR
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sham bimatoprost SR performed using the same procedure as for Bimatoprost SR using an needleless applicator that touches the eye at the area of insertion but does not deliver an implant into the anterior chamber.
Trial: NCT01617005
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive tocilizumab treatment according to effective official SPC. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
Trial: NCT04780984
Drug: Tiotropium bromide inhalation solution
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide inhalation solution
Trial: NCT03416569
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nicotine patch (7 mg/24 hrs) + placebo capsule
Trial: NCT03416569
Drug: Prazosin
RxNorm normalized name: Prazosin
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo patch (7 mg/24 hrs) + prazosin capsule (1 mg)
Trial: NCT01324739
Drug: human BNP-32
RxNorm normalized name: BNP-32
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3pmol/kg/min infusion
Trial: NCT01011699
Drug: sevelamer
RxNorm normalized name: Sevelamer
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titration phase with sevelamer (Renagel) with the aim of phosphatemia control before 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week).
Trial: NCT01011699
Drug: cinacalcet
RxNorm normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After 6 months of treatment, patient screening on PTH level:~For patients with PTH \> 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH \< 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be \< 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia \< 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.~A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l.
Trial: NCT01130311
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
Trial: NCT01130311
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: normal saline, intramuscular preperation,given in 2 doses at week 0 and week 4 of trial
Trial: NCT00008320
Drug: ceramide
RxNorm normalized name: ceramide
DrugBank: Ceramide NP (DB14111)
FDA approved: no
EMA approved: no
PMDA approved: no